Sweating the Details: An Interview with Jamie Thomson by Gitschier, Jane
Interview
Sweating the Details: An Interview with Jamie Thomson
Jane Gitschier*
Departments of Medicine and Pediatrics, Institute for Human Genetics, University of California San Francisco, San Francisco, California, United States of America
If you had to name the most controver-
sial scientific achievement of the past
decade, you’d be hard pressed to top the
development of human embryonic stem
[ES] cells. Human ES cells followed on the
heels of another major technological
advance—Dolly, the cloned ewe. Togeth-
er, these remarkable breakthroughs have
stimulated great public interest and have
ushered in a new era in the exploration of
human biology. At the center of the ES
maelstrom is a soft-spoken and intensely
private scientist from the Genome Center
at the University of Wisconsin. Jamie
Thomson (Image 1), who is also Director
of Regenerative Biology at the new
Morgridge Institute for Research and the
founder of two companies, is purposeful,
with an obvious knack for a difficult
experiment, yet seems a bit uncomfortable
in the limelight his work has generated.
Trained as a veterinarian and research
scientist, Thomson had a dual passion for
experimental embryology and species
preservation. He was just emerging from
his post-doctoral fellowship at the Primate
Center in Oregon when he moved to
Wisconsin. He was hired there with the
specific goal of deriving ES cells from
primates, a feat he accomplished in short
order. Within a few years, working closely
with the ethics and in vitro fertilization
(IVF) communities, he succeeded in deriv-
ing human ES cells. More recently,
pushing the boundaries of human devel-
opmental biology even further, his labo-
ratory reported the creation of induced
pluripotent stem (IPS) cells, a way for
turning human differentiated cells back
into ES cells.
I sought out Jamie in mid-April during a
cold, umbrella-inverting rainstorm. With
daughter in tow, I borrowed my sister’s
red MINI Cooper and headed off from
her home in Milwaukee to Madison. After
struggling with the concept of paying for
parking by phone, we puddle-jumped our
way to Thomson’s building and literally
stumbled into a sign celebrating the first
synthesis of DNA, one of a series of
placards that extol the long line of
important discoveries made at this Uni-
versity. I located Thomson in his office
down a quiet hallway, abandoned my
daughter to the tea room and her assigned
reading in To Kill a Mockingbird, and to the
soothing sound of the University of
Wisconsin coal train outside his window,
we began the interview.
Gitschier: The first thing I want to talk
to you about is how you got into this
business.
Thomson: In college, I liked biology,
and I wasn’t quite sure what I wanted to
do with it. I was good at mathematics. I
was trying to find a way to put the two of
them together in a biophysics major. But I
was spending a summer at Woods Hole,
doing population biology stuff, because I
thought that was a good overlap with
understanding mathematics.
Gitschier: What kind of organism
were you working on?
Thomson: I was working on the salt
marshes with Melampus bidentatus, which is
a little snail. And I was up to my knees in
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Sippewissett Marsh, and I decided that I
liked mathematics, but I wasn’t really into
counting things that large. So I was
looking around for a way to put these
things together, and I liked developmental
biology still.
One night, I went to a lecture by a guy
from Stanford at the time. His name was
Paul Ehrlich, an ecologist type, and he
gave a talk on endangered species. He
quickly went through this argument that
zoos would have no positive impact [on
preventing extinction] because of the size
and the numbers [of endangered species]
involved. If you filled up the zoos with that
number, you’d hit only a very small
number of species, and you’re not going
to do anything significant.
I was sitting in the audience going
‘‘Hmm, I thought you could freeze things
like sperm and eggs.’’ I was a biophysics
major, what did I know? But I thought
that if you went out and collected enough
sperm and enough eggs, you could keep
fairly large repositories and the breeding
problem could be managed artificially
through this stock of frozen stuff.
That same evening on the news there
was a woman named Barbara Durant with
Walter Cronkite at the San Diego Zoo,
and she had this rat that had come from a
frozen embryo.
So all of this happened in one day! And
I looked at that and said, ‘‘I’d like to do
that! I wonder what kind of degree would
be useful for that?’’
Gitschier: What year was this?
Thomson: This would have been
1980, between my junior and senior year.
I had an undergraduate advisor named
Frederick Meins who, even though I had a
very good grad school advisor, has been
my mentor in life. When I was 18, he told
me all these wonderful stories about these
biologists, one of whom was Jared Dia-
mond, who would be on the cover of the
New York Times for discovering some new
species in New Guinea. But he was also a
biophysics professor! And I thought, ‘‘Hey,
I could do something like that!’’
So the plan was, in my naive undergrad-
uate ambition, to do practical veterinary
things that would allow me to manipulate
embryos of endangered species, and at the
same time, do basic developmental biology.
It turned out that Penn had a combined
VMD/PhD program. So, I went to grad-
uate school there in a basic mouse
developmental biology lab [with Davor
Solter] at the Wistar Institute.
When I went to be a post-doc, I decided
to switch to primates, to go back to this
original idea. There are about 200 species
of primates, depending on whether you
are a lumper or a splitter, and at that time,
about half were endangered or threatened.
And it seemed like a focused population
with biomedical relevance. And if I did
basic developmental biology in primates, it
would be directly applicable to humans in
a way that mouse is not.
So I went off to the Oregon Primate
Center, which at that time had the best
embryo recovery and in vitro fertilization
[IVF] program for nonhuman primates. I
learned a lot about doing IVF and
experimenting with primate embryos
and, at the same time, I initiated some
fieldwork in Sulawesi [in central Indone-
sia] with an endangered primate called
Macaca nigra. They had gone from 300,000
in the ’70s down to about 3,000 by the
time I got there. I was going to attempt to
dart the remaining male population,
collect semen, and bring it back home—
some preliminary stuff to get a grant. I
think the grant came in second and they
[the NIH] decided to fund only one. So I
started looking around for a job, because
things were ending in Oregon.
I moved here [Wisconsin] because John
Hearn was the director of the Primate
Center here, and he had worked out
methods to have in vivo–recovered em-
bryos. He hired me specifically to derive
primate embryonic stem cells.
Gitschier: Were these embryos the
product of in vitro fertilization?
Thomson: No, these were natural
ones, flushed out in a nonsurgical proce-
dure. We got very high-quality embryos
that don’t require culture. The advantage
[of using natural embryos] was that back
then, the culture medium [for IVF-gener-
ated embryos] was pretty bad, and you
couldn’t go from one cell to blastocyst and
have a real healthy product.
So I came here specifically to derive
primary embryonic stem cells.
Gitschier: But wait, is this a leap? You
were interested in saving embryos that
could then be used to regenerate lost
species, potentially.
Thomson: No, the intent was to
establish a robust experimental embryolo-
gy in primates that could make up for
some of the species-specific differences in
mouse. Mouse is simply a better model,
there is no way around that, but in some
ways it does not reflect human develop-
ment very well. And in Oregon, despite
the fact that they had the best embryo
recovery program from IVF in the world,
they were completely starved for embry-
onic material.
In mouse, you can sit down and do 200
embryos in a day—it’s not a big deal. The
cost here for the natural flushed [primate]
ones was $2,000 per embryo! So you
couldn’t do a thousand of them, you
couldn’t do two of them! It was almost
impossible.
So, the rationale for me to derive the
primary embryonic stem cells was to get a
sustainable primate material that would
recapitulate normal human events better
than mouse ES cells in a way that the
material is not limiting.
Gitschier: OK!
Thomson: It’s all about experimental
embryology. And Hearn had been Direc-
tor of the research branch of London Zoo.
He had a strong interest in promoting
conservation of primates when he came
here. And I still had this idea that I could
do both [experimental embryology and
conservation], until I derived embryonic
stem cells, and then it kind of took over my
life.
Since 1995, when we published the first
rhesus embryonic stem cells, those other
interests in endangered species have been
pushed aside.
Gitschier: Would you like to get back
to that sometime?
Thomson: Part of me wants to. I have
a young family now. Mucking through the
jungle is not going to happen any time
soon. Although it is attractive and I would
probably enjoy doing that more than what
I’m doing now.
Gitschier: Let’s talk about 1995 and
your work on primate embryonic stem
cells. It sounds as though it worked fairly
quickly. What did you do that was
different from the mouse?
Thomson: It was sweating the details.
Superficially it was the same. The primate
cells are not dependent on LIF [leukemia
inhibitory factor], but feeder layers worked
also for these cell lines. We were very
careful with the culture conditions and got
it to work. Later on, we and others
discovered that cytokines that mediate
self-renewal are distinct between the two
cell types, but we didn’t know it at the
time.
Gitschier: Why had no one done it
before? Mouse ES cells were derived in
1981. Fourteen years later…
Thomson: In the middle 1980s, people
in Britain had already tried to do human
ES cells and failed. And failed probably
because the embryos weren’t very good,
because the culture medium was bad, and
they were still thinking they were like
mouse ES cells, which they are not. Even
though the conditions we use involve
fibroblasts, as in mouse ES cells, the
finesse is different, the timing is different,
the splitting is different. Some very good
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and I don’t know why they failed, but they
did fail.
We had good access to very, very high-
quality primate material. We were very
quickly successful with that, and because
we had that experience, as soon as we had
high-quality human embryos, we got it. If
you look at the numbering of our cells
lines, it goes from H1 to H14. H1 is the
very first human embryo we tried, because
of our experience with primate. And the
culture medium was just getting better at
the time we were developing our cells.
Gitschier: What was different about
the medium?
Thomson: David Gardner, working in
Australia and now in Colorado, developed
a new generation of media; it was
optimized for human material. If you put
mouse media on human embryos, it
doesn’t work very well. It’s nothing to do
with a special growth factor, it’s just
optimizing salts and glucose, stuff like that.
Gitschier: So it’s a medium for the
embryos themselves, not the stem cells.
Thomson: Right. Prior to that we
couldn’t get a quality blastocyst to try it
[stem cell derivation] on. With the primate
work, we didn’t need the medium because
we went straight to the derivation process,
because the [in vivo–recovered] embryos
were high quality.
Gitschier: So were you communicat-
ing with the people who do IVF and who
actually culture the embryos?
Thomson: Oh yeah. Jeff Jones was the
person who actually did that and Gardner
had a graduate student who became a
post-doc at UW, and that post-doc helped
Jeff introduce that medium into the IVF
clinic. So this clinic was among the first to
use that new generation of media. Part of
the reason we were successful is that Jeff is
very good at his job.
Gitschier: So, 1995, you were still
interested in primates for primates’ sake,
really, looking at early embryonic devel-
opment. Why did you then make the leap
to humans?
Thomson: At the time we derived the
primate stem cells, I really wasn’t planning
to do it. I assumed that once we published
the primate work, someone would do the
human work very quickly. We have a very
small IVF unit here, with very limited
access to embryos, and I thought that
every IVF lab in the world would be doing
this quickly.
Gitschier: And presumably, it wasn’t
even a primary interest of yours.
Thomson: No, though it was obvious
that it was really important. I just thought
someone else would do it. But as the
months wore on and nobody did it, I
decided to try it here.
Gitschier: And did you do this with
your own hands?
Thomson: Yeah, I did all those
experiments.
At the end of 1994/95, I spoke to our
ethics people here. In 1994, Clinton asked
[Harold] Varmus [then director of the
NIH] to start a commission to look at
embryo experimentation and Alto Charo,
who is a lawyer here, sat on that panel. So
I asked her, ‘‘Hey, if I were to do this,
what should I do?’’ I was really lucky that
she was here. Also, the head of our IRB,
Norm Fost, was very supportive.
Things have basically been ‘‘won’’ now,
from a public perception. But back then,
everybody was really scared. They were
scared about public funding. They were
scared about personal safety. While the
University wasn’t ecstatic about having me
around, because it made everybody ner-
vous, they were all really supportive, and
in particular those two people helped me
put the consent process through in a very
reasonable way.
Gitschier: Did you personally have
any ethical issues with the human embry-
onic stem cells?
Thomson: I thought about it a lot
prior to doing it, and I decided that if these
are embryos that the patients have already
decided to throw out, that it is a better
ethical choice to use them for something
useful. And it’s actually a fairly complex
problem about how you think about that.
Gitschier: At the time was there
already some kind of prohibition to
funding human embryonic research?
Thomson: Yeah, it was actually worse
then. The Dicky amendment [1996] said
something to the effect that no federal
money can be used to damage or jeopar-
dize a human embryo.
Gitschier: So in addition to getting the
IRB approval, you also had to get money.
Thomson: Right, and that’s what
made the University so nervous, because
they would lose all the federal funding if I
screwed up somehow.
Gitschier: No pressure! Is that when
you started to be supported by Geron
[Corporation]?
Thomson: I asked the University for
about $20,000, and they said ‘‘No.’’ And
the next week Geron walked into my office
and I said, ‘‘Well if the Federal govern-
ment won’t fund me and the University
won’t fund me, great!’’
Mike West was the fellow at Geron at
the time. He’s got the vision thing down.
He understood that this was important
before other people did. I accepted funds
from Geron until President Bush made it
legal to use federal funds, and I have
declined them ever since.
Gitschier: But you need to use existing
cell lines.
Thomson: I’ve used the same five cell
lines for 10 years now.
Gitschier: You made a comment in
another interview: ‘‘I didn’t know we’d be
stuck with these cells.’’
Thomson: Yeah, I assumed people
would derive new ones right away.
Gitschier: But the implication is that
these early embryonic stem cells might not
be as good as ones that might be derived
later.
Thomson: Actually, to be stronger
than that, I very specifically did not keep
track of stuff, like lot numbers, because I
didn’t want to have to do the paperwork
for FDA-like stuff. I figured, this is nice
proof of principle. We’ll just derive
MORE! If people want to do a GMP
[good manufacturing process], let them.
The FDA actually wants tracking now.
Gitschier: Let’s talk about how your
life changed then in 1998 with the
publication of human stem cells.
Thomson: Well, Dolly had been
cloned the year before, so I was kind of
prepared, because I could see what Ian
Wilmut had to go through.
Gitschier: And what did he have to go
through?
Thomson: Hell. It doesn’t allow you
much time for doing your work anymore.
So I was wrong about some things. For
one thing, the media were pretty positive,
but it wasn’t clear prior to publication how
it would go. On the whole, the initial
science reporting especially was superb
and the story was accurate.
The other thing I miscalculated was that
I figured people would have a pretty short
attention span. But we’re 10 years in, and
it is still a big story. I think it has to do with
politics and who got elected to the White
House more than anything, because I
think had somebody else been elected, it
[stem cell research] would have been
‘‘normal’’ science a long time ago.
Gitschier: And now, you’ve developed
a new technology that may obviate some
of these political and funding issues:
Induced pluripotent stem [IPS] cells. Set
the stage for that for me.
Thomson: The stage was Dolly real-
ly—that changed the mindset of develop-
mental biologists in a big way, including
mine. About 5 years ago, I hired the post-
doc [Junying Yu] who was the first author
on our paper [published in 2007]. My
conversation with her at the time was that
we have to try this, even though it
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probably like a 20-year problem, because
the thought back then was that it has just
got to be really complicated. All those little
factors, and how can you manipulate all of
those? It didn’t really seem sensible.
I thought by doing such a combinatorial
screen, we might get PARTIAL repro-
gramming in some way.
Gitschier: Describe what you mean by
combinatorial screen.
Thomson: I’ll tell you what we did,
and it was very similar to what Yamanaka
did in the mouse. We were doing it at the
same time, but he got ahead of us because
mouse work is actually much faster than
human work, although we actually had a
partially defined system with a more
complicated set of factors prior to publi-
cation of his mouse work.
Back in the ’70s, it was found that if you
fuse blood cells with embryonic carcinoma
[EC] cells—ES cells hadn’t been derived
yet—that within that heterokaryon, the
dominant phenotype could either be the
blood cell or the EC cell, but it was often
the EC cell. So that was early evidence for
reprogramming.
We started to do similar experiments
several years ago, in which we took ES
cell–derived blood cells. We had a well-
defined, cloned, expandable hematopoiet-
ic cell type that we used in cell fusions for a
model for reprogramming, and we showed
that the dominant phenotype was the ES
cell.
We did gene expression analysis of both
those cell types and started to clone genes
that were specifically enriched in ES cells.
So Junying cloned between 100 and 200
genes, and she started taking pools of them
to test for reprogramming ability and we
used a knock-in human ES cell line that
turns green and gets drug resistant when it
reprograms to an ES cell state. Last
summer, Junying kept paring it down until
there were four factors, and we repeated it
in different cell types.
It was kind of a dumb thing to do—it
worked and that is nice. If you look at the
factors we found, OCT4, SOX2, and
NANOG—they’re everybody’s favorite
genes already—these are key pluripotency
genes. But we had this mindset, which was
so strong, that it HAD to be complicated,
we just never tested them! It would have
been a lot easier to just test them 5 years
ago and gotten it done in a month or two!
Gitschier: These IPS cells won’t be
restricted in terms of federal funding?
Thomson: No. That changes every-
thing.
Gitschier: Do you think people will
work both on IPS and ES cells?
Thomson: For our lab, we’ve been
growing the same ES cells for 10 years—
we’re not going to stop that anytime soon.
On the other hand, as new people enter
the field, I would guess that most of them
will be deriving IPS cell lines and not ES
cell lines, and that over time, ES cells will
take a smaller percentage of people’s
attention. It comes down to whether they
are equivalent or not, which we don’t
know for sure yet. But my sense is that
they will be. If you can’t tell them apart,
why inherit all the baggage of the
embryonic stem cells when you don’t have
to?
Gitschier: So, what are you going to
work on now?
Thomson: I’m interested in whether
this is the first example of many. There are
other cell fusions between other cell types,
and it suggests that other similar lateral
transitions could be artificially induced.
Nobody has done systematic screens for
those lateral transitions in a similar way,
probably because everybody thought that
was too complicated. There is probably no
clinical utility for making a heart cell out of
nerve cell, but that is the kind of thing
we’re going to see. Can we understand
enough about the biology that we can
predict which factors are needed without
doing these combinatorial screens? I don’t
know precisely how you get this into
regenerative medicine, but when you
actually think about the nuts and bolts of
how you’d introduce something into a
patient, that is challenging.
The long-term goal of regenerative
medicine is to cause tissue to regenerate,
not to do cell transplants. And for tissues
to regenerate that don’t normally do so,
you’re talking about changes in cellular
states that are physiologically disallowed.
So if you understand what creates those
barriers and how you can overcome them,
it could well lead to real robust regener-
ative medicine. And that one is DEFI-
NITELY a 21st century problem that
won’t go away as fast as the last ones.
Gitschier: Are you having fun?
Thomson: Yes and no. It’s very
satisfying—that what I do I think is
important. But day to day, most jobs are
just stressful, you know? Even if you are
good at it, and things are going well.
Gitschier: Do you think that part of
the stress, though, is the nature of the
problem itself and the competition?
Thomson: Yeah, the competition has
gotten—I won’t say out of hand—that is
the nature of the business—if something is
perceived as important, there will be
competition, but it clearly makes it a lot
less fun, and I don’t see a way around that.
Especially the reprogramming stuff over
the last year or so—everybody is doing
that now! That was one of nice things
about doing the primate ES cells—nobody
cared!
By nature, I am a loner. At the last
ISSCR [International Society for Stem
Cell Research] meeting, I don’t know how
many people show up now, but based on
my personality, too many! I do better one
on one or in small groups.
Gitschier: But this is a path you’re
going to be on for a while.
Thomson: Yes, and I’m looking for
little niches that I can find fun again for
which there is not a head-to-head compe-
tition, ‘cause at the end of the day, if you
publish a week or two before somebody
else, it’s kind of futile, isn’t it?
Gitschier: Final thoughts?
Thomson: The point that I want to
make is that a lot of the enthusiasm and
emotion that has driven human embryonic
stem cells is the idea that we’ll use this for
transplantation and cure diseases like
Parkinson, and while I think in limited
cases that might be true, I think broadly it
will prove extraordinarily challenging.
And if you look at the field say 10 to 20
years from now, there’ll be some stellar
successes in the transplantation realm, but
there’ll be a lot of failures, and I think
people are ill-prepared for the risks of a
new technology like this.
If you look at the early days of bone
marrow transplants, most people died! I
think a single death in this area is going to
create an uproar, given the politics
involved, and there will be such deaths,
because the diseases people are contem-
plating [treating] are very serious diseases.
So if you look at the pie of things that
will be important 20 years from now, my
belief is that the broader applications are
in the understanding of the human body,
and that, similar to recombinant DNA, it
will be pervasive and everybody is going to
use it and they won’t call themselves ‘‘stem
cell biologists’’ anymore. It’ll just be
something to get access to the human
body. And I think that WILL profoundly
change human medicine in ways that I
can’t even predict.
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